January 21, 2007 -- So far in 2007, it has been a clean sweep for biotech. In each of the three weeks of the year, the Centient Biotech 200™ has posted a gain. Last week, the CBT 200™ climbed another 34 points to 4112, a new record and a gain of .83%. Breadth, however failed to confirm the upward movement. Next week, earnings season begins in earnest. Also next week, Oculus is scheduled to make its IPO, and XTENT follows the week after. The 2006 IPO Class continued to do well, rising 1.4% last week and 45% since pricing. On the CBT 200™ list, the biggest winner was Corautus with a 62% gain, climbing on merger talks; Ciphergen gained 26% after announcing it would develop a blood test for peripheral arterial disease; Neurocrine was 13.5% higher after being recommended by Lehman Brothers; Genitope was up 12.6% and GPC Biotech added on 11.2%, both without releasing any news. More details...
